Kelonia investor Venrock will clear a 45-fold return on startup's sale to Lilly
Kelonia投资方Venrock将在初创公司售予礼来时获得45倍回报

The investor Venrock will make $900 million on a relatively small $20 million investment into Kelonia Therapeutics, which on Monday agreed to sell itself to Eli Lilly in a $3.25 billion upfront deal.
投资方Venrock将凭借对Kelonia Therapeutics相对较小的2000万美元投资获利9亿美元；该公司于周一同意以32.5亿美元的预付款将自身出售给礼来。